CareDx announces launch of AlloSure 3.0
CareDx announces the launch of AlloSure 3.0, the next iteration in continued transplant patient-focused improvements. CareDx has new data showing AlloSure provides more in-depth insights into patients with TCMR1A and borderline rejection. Data suggests the heterogeneous pattern of these diagnoses is associated with varying degrees of organ injury. The prospective, multicenter analysis across leading transplant centers shows that AlloSure remained low in patients that continued to have a stable clinical profile and was elevated in patients that had declining clinical profiles. This highlights the ability to use AlloSure to better risk stratify transplant patients with borderline, TCMR1A, and subclinical rejection.